Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P10636 (tau protein)
 5,110 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Roles of protein kinases in mediating adaptive neuronal responses to activation of signal transduction pathways are well known. Recent findings suggest that kinases may also be involved in pathological processes in the nervous system. The present study employed cultured human cerebral cortical neurons to test the hypothesis that overactivation of protein kinase C (PKC) can result in neurodegeneration. Phorbol 12-myristate 13-acetate (PMA), an activator of PKC, caused the degeneration of neurons over a period of 3-24 h. The PKC inhibitor H-7 prevented the neurodegeneration normally caused by PMA, and an inactive phorbol (4 alpha-phorbol 12,13-didecanoate; PDD) did not cause neurodegeneration. The neurodegeneration caused by PMA was independent of calcium influx. Immunoreactivity toward antibodies that recognize the microtubule-associated protein tau in Alzheimer neurofibrillary tangles (Alz-50 and 5E2) was greatly increased in neurons exposed to PMA. The antigenic changes were prevented by H-7. These findings indicate that high levels of activation of PKC can cause neurodegeneration and are consistent with the possibility that altered cellular signaling contributes to pathological neuronal degeneration in the intact nervous system.
 ...
PMID:Evidence for the involvement of protein kinase C in neurodegenerative changes in cultured human cortical neurons. 201 10

Characteristic tau isoform composition of the insoluble fibrillar tau inclusions define tauopathies, including Alzheimer's disease (AD), progressive supranuclear palsy (PSP) and frontotemporal dementia with parkinsonism linked to chromosome 17/frontotemporal lobar degeneration-tau (FTDP-17/FTLD-tau). Exon 10 splicing mutations in the tau gene, MAPT, in familial FTDP-17 cause elevation of tau isoforms with four microtubule-binding repeat domains (4R-tau) compared to those with three repeats (3R-tau). On the basis of two well-characterised monoclonal antibodies against 3R- and 4R-tau, we developed novel, sensitive immuno-PCR assays for measuring the trace amounts of these isoforms in CSF. This was with the aim of assessing if CSF tau isoform changes reflect the pathological changes in tau isoform homeostasis in the degenerative brain and if these would be relevant for differential clinical diagnosis. Initial analysis of clinical CSF samples of PSP (n = 46), corticobasal syndrome (CBS; n = 22), AD (n = 11), Parkinson's disease with dementia (PDD; n = 16) and 35 controls revealed selective decreases of immunoreactive 4R-tau in CSF of PSP and AD patients compared with controls, and lower 4R-tau levels in AD compared with PDD. These decreases could be related to the disease-specific conformational masking of the RD4-binding epitope because of abnormal folding and/or aggregation of the 4R-tau isoforms in tauopathies or increased sequestration of the 4R-tau isoforms in brain tau pathology.
 ...
PMID:Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies. 2299 75

The H1 haplotype of the MAPT gene influences the risk of PD and has been related to the development of PDD. We evaluated the influence of MAPT haplotypes on the expression of motor features in PD patients. We genotyped, for the MAPT haplotypes H1 and H2, a sample of 181 PD patients with distinct clinical subtypes: tremor dominant and non-tremor dominant (NTD). Our results indicate that the MAPT haplotypes contribute to the expression of motor features of PD. H1 homozygous PD patients are significantly more likely to present a NTD phenotype, a clinical subtype characterized by widespread pathological degeneration, than H2 carriers.
...
PMID:Clinical subtypes in Parkinson's disease: the impact of MAPT haplotypes. 2425 35